Top-Rated StocksTop-RatedNASDAQ:HRMY Harmony Biosciences (HRMY) Stock Price, News & Analysis $35.60 +0.15 (+0.43%) As of 10:59 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Harmony Biosciences Stock (NASDAQ:HRMY) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Harmony Biosciences alerts:Sign Up Key Stats Today's Range$35.25▼$35.8650-Day Range$31.57▼$37.5252-Week Range$26.47▼$41.61Volume42,101 shsAverage Volume663,383 shsMarket Capitalization$2.04 billionP/E Ratio13.63Dividend YieldN/APrice Target$51.00Consensus RatingBuy Company Overview Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also offers HBS-102, a melanin-concentrating hormone receptor 1 for MCH neurons. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania. Read More Harmony Biosciences Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks97th Percentile Overall ScoreHRMY MarketRank™: Harmony Biosciences scored higher than 97% of companies evaluated by MarketBeat, and ranked 51st out of 935 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.5 / 5Analyst RatingBuy Consensus RatingHarmony Biosciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 8 buy ratings, 1 hold rating, and no sell ratings.Amount of Analyst CoverageHarmony Biosciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Harmony Biosciences' stock forecast and price target. Earnings and Valuation4.4 / 5Proj. Earnings Growth27.98% Earnings GrowthEarnings for Harmony Biosciences are expected to grow by 27.98% in the coming year, from $2.43 to $3.11 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Harmony Biosciences is 13.53, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 27.81.Price to Earnings Ratio vs. SectorThe P/E ratio of Harmony Biosciences is 13.53, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 28.20.Price to Earnings Growth RatioHarmony Biosciences has a PEG Ratio of 0.49. PEG Ratios below 1 indicate that a company could be undervalued.Price to Book Value per Share RatioHarmony Biosciences has a P/B Ratio of 3.07. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harmony Biosciences' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted10.14% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Harmony Biosciences has recently increased by 19.14%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarmony Biosciences does not currently pay a dividend.Dividend GrowthHarmony Biosciences does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted10.14% of the float of Harmony Biosciences has been sold short.Short Interest Ratio / Days to CoverHarmony Biosciences has a short interest ratio ("days to cover") of 6.4.Change versus previous monthShort interest in Harmony Biosciences has recently increased by 19.14%, indicating that investor sentiment is decreasing significantly. News and Social Media4.1 / 5News Sentiment1.30 News SentimentHarmony Biosciences has a news sentiment score of 1.30. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.04 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 14 news articles for Harmony Biosciences this week, compared to 7 articles on an average week.Search Interest10 people have searched for HRMY on MarketBeat in the last 30 days. This is an increase of 11% compared to the previous 30 days.MarketBeat Follows7 people have added Harmony Biosciences to their MarketBeat watchlist in the last 30 days. Company Ownership3.3 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Harmony Biosciences insiders have not sold or bought any company stock.Percentage Held by Insiders23.60% of the stock of Harmony Biosciences is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions86.23% of the stock of Harmony Biosciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harmony Biosciences' insider trading history. Receive HRMY Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harmony Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address HRMY Stock News HeadlinesAnalysts Offer Insights on Healthcare Companies: Harmony Biosciences Holdings (HRMY) and Alibaba Health Information Technology (OtherALBHF)July 28 at 11:11 PM | theglobeandmail.comHarmony Biosciences Advances Pipeline While Navigating Analyst CautionJuly 24, 2025 | finance.yahoo.comA $674B Industry Missed the Bigger PictureTV video streaming exploded into a $674.25B market in 2024—driven by the hours we spend lost in entertainment. But there’s a much bigger habit consuming our time, with value that’s waiting to be unlocked. Smartphone screen time. We spend over 30 hours a week glued to our phones. Mode Mobile is pioneering ways to turn those hours into real income. Their EarnPhone unlocks 19 revenue streams from everyday phone use, helping users earn over $325M so far. Deloitte crowned them North America’s fastest-growing software company in 2023 after their revenue soared 32,481% from 2019-2022. But this industry is still in its infancy, and you can invest in the company that’s at the forefront of unlocking its value.July 30 at 2:00 AM | Mode Mobile (Ad)HC Wainwright Issues Positive Estimate for HRMY EarningsJuly 24, 2025 | americanbankingnews.comHarmony Biosciences to Report Second Quarter 2025 Financial Results on August 5, 2025July 22, 2025 | businesswire.comHarmony Biosciences (NASDAQ:HRMY) Earns Buy Rating from Analysts at Truist FinancialJuly 22, 2025 | americanbankingnews.comHRMY vs. ILMN: Which Stock Should Value Investors Buy Now?July 15, 2025 | msn.com3 Reasons Growth Investors Will Love Harmony Biosciences (HRMY)July 15, 2025 | msn.comSee More Headlines HRMY Stock Analysis - Frequently Asked Questions How have HRMY shares performed this year? Harmony Biosciences' stock was trading at $34.41 at the beginning of 2025. Since then, HRMY stock has increased by 3.0% and is now trading at $35.45. How were Harmony Biosciences' earnings last quarter? Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) announced its earnings results on Tuesday, May, 6th. The company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.59 by $0.19. The company's revenue was up 19.5% compared to the same quarter last year. Read the conference call transcript. When did Harmony Biosciences IPO? Harmony Biosciences (HRMY) raised $101 million in an initial public offering on Wednesday, August 19th 2020. The company issued 4,700,000 shares at $20.00-$23.00 per share. Goldman Sachs, Jefferies and Piper Sandler served as the underwriters for the IPO. Who are Harmony Biosciences' major shareholders? Harmony Biosciences' top institutional shareholders include Capital Management Corp VA (0.61%), CX Institutional (0.36%), Atle Fund Management AB (0.15%) and Ruffer LLP (0.15%). Insiders that own company stock include Jack Nielsen, Andreas Wicki, Sandip Kapadia, John C Jacobs, Jeffrey M Dayno and Jeffrey Dierks. View institutional ownership trends. How do I buy shares of Harmony Biosciences? Shares of HRMY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harmony Biosciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harmony Biosciences investors own include NVIDIA (NVDA), Meta Platforms (META), Broadcom (AVGO), Advanced Micro Devices (AMD), Adobe (ADBE), ServiceNow (NOW) and Arista Networks (ANET). Company Calendar Last Earnings5/06/2025Today7/30/2025Next Earnings (Estimated)8/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:HRMY CIK1802665 Webwww.harmonybiosciences.com Phone484-539-9800FaxN/AEmployees200Year FoundedN/APrice Target and Rating Average Price Target for Harmony Biosciences$51.00 High Price Target$70.00 Low Price Target$33.00 Potential Upside/Downside+42.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage10 Analysts Profitability EPS (Trailing Twelve Months)$2.62 Trailing P/E Ratio13.60 Forward P/E Ratio14.72 P/E Growth0.49Net Income$145.49 million Net Margins20.53% Pretax Margin26.48% Return on Equity24.32% Return on Assets15.92% Debt Debt-to-Equity Ratio0.22 Current Ratio3.67 Quick Ratio3.63 Sales & Book Value Annual Sales$714.73 million Price / Sales2.87 Cash Flow$2.95 per share Price / Cash Flow12.14 Book Value$11.56 per share Price / Book3.10Miscellaneous Outstanding Shares57,420,000Free Float43,872,000Market Cap$2.05 billion OptionableOptionable Beta0.83 Social Links The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free Report This page (NASDAQ:HRMY) was last updated on 7/30/2025 by MarketBeat.com Staff From Our PartnersAI Frenzy Could Send ‘EarnPhone’ SoaringThe hidden fuel behind AI? Your phone. Billions of data points — from your clicks, swipes, scrolls, and sea...Mode Mobile | SponsoredDrone Company Secures Major Defense Contract Amid Sweeping Policy ShiftOn July 10th, the White House and DoD announced a sweeping new directive to fast-track U.S. drone dominance. ...The Tomorrow Investor | SponsoredMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new comp...The Oxford Club | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredWhy AMZN, GOOG, MSFT might destroy NVDAInvesting Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla an...InvestorPlace | SponsoredElon Musk: “This will transform civilization as we know it.”Robots are no longer science fiction — they’re the next trillion-dollar megatrend. According to Forbes, by ...Weiss Ratings | SponsoredI’d rather trade news like this than gamble on hypeReal traders are watching Nvidia’s next move—after U.S. approval to resume chip sales to China. This reversal ...Timothy Sykes | SponsoredGenesis 14:13-17 [HIDDEN MEANING?]A mysterious Bible verse from Genesis may hold the key to unlocking what one expert calls an “American birthri...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harmony Biosciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harmony Biosciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.